Résumé
To explore the action mechanism of Qiangji Jianli Capsule (QJJLC) treating myasthenia gravis.
Internal receptor permeation and degradation test were performed.
Volume of receptor permeation in the group with QJJLC at 96 hours was 902.50 +/- 37.48 cpm/mg, while that of control group 738.45 +/- 35.41 cpm/mg. Half-life of receptor degradation in treatment group was 52 hours and that of control 38 hours. Their difference was very significant (P < 0.001).
QJJLC could accelerate permeation of N-aectylcholine receptor to surface of diaphragm cell membrane and decelerate receptor degradation. It could also increase accumulative amounts of functional receptor in unit time and keep dynamic equilibrium of receptor metabolism in pathologic condition.